Finland -based implantable medical devices manufacturer BonAlive Biomaterials has announced the signing of a multi-year exclusive distribution agreement with Olympus Biotech, a wholly owned company of Olympus Corporation focused on minimally-invasive regenerative therapies in bone and soft tissues.

As part of the agreement, Olympus Biotech will become exclusive distributor for the BonAlive Biomaterials BonAlive granules product line in Germany, France and the UK.

The product line covers regenerative products for orthopaedic and trauma surgeries.

BonAlive Biomaterials CEO Fredrik Ollila said the firm’s new partnership with Olympus will help in providing a complete portfolio of bone regeneration products to the community of orthopaedic and trauma surgeons.

"The establishment of a complete product offering will generate value and bring new opportunities in treatment of chronically infected bone," Ollila added.